OMEROmeros Corp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz...

Key PointsHeartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ: OMER) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp (Symbol: OMER), where a total of 11,925 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 60.6% o...

EMA rejects Omeros' Yartemlea for TA-TMA, citing insufficient efficacy data, despite FDA approval and U.S. launch.read more...

European regulators issued a negative opinion on Yartemlea, Omeros’ therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the companys marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell...

Key PointsNovoCure maintains a commercialized revenue base through its proprietary Tumor Treating Fields oncology platform...